Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.

Alastair J H Brown | Sophie J Bradley | Fiona H Marshall | Giles A Brown | Kirstie A Bennett | Jason Brown | Julie E Cansfield | David M Cross | Chris de Graaf | Brian D Hudson | Louis Dwomoh | João M Dias | James C Errey | Edward Hurrell | Jan Liptrot | Giulio Mattedi | Colin Molloy | Pradeep J Nathan | Krzysztof Okrasa | Greg Osborne | Jayesh C Patel | Mark Pickworth | Nathan Robertson | Shahram Shahabi | Christoffer Bundgaard | Keith Phillips | Lisa M Broad | Anushka V Goonawardena | Stephen R Morairty | Michael Browning | Francesca Perini | Gerard R Dawson | John F W Deakin | Robert T Smith | Patrick M Sexton | Julie Warneck | Mary Vinson | Tim Tasker | Benjamin G Tehan | Barry Teobald | Arthur Christopoulos | Christopher J Langmead | Ali Jazayeri | Robert M Cooke | Prakash Rucktooa | Miles S Congreve | Malcolm Weir | Andrew B Tobin
Cell | 2021

Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects. Here we aimed to design the drug properties needed for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissue-based assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans. Through this approach, we rationally designed the optimal properties, including selectivity and partial agonism, into HTL9936-a potential candidate for the treatment of memory loss in Alzheimer's disease. More broadly, this demonstrates a strategy for targeting difficult GPCR targets from structure to clinic.

Pubmed ID: 34822784 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: MR/P019366/1
  • Agency: Wellcome Trust, United Kingdom
    Id: 201529/Z/16/Z
  • Agency: Cancer Research UK, United Kingdom
    Id: C596/A17196

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Noldus (tool)

RRID:SCR_004074

Commercial organization that develops tools and systems for measurement and analysis of animal and human behavior. They develop instrumented home cage systems, in which rodent behavior and ultrasonic vocalizations can be measured in a non-intrusive manner. Furthermore, they develop computer vision and pattern recognition technology for automated behavior detection. They believe that this approach has significant potential in research on animal models for Autism Spectrum Disorder.

View all literature mentions

CCP4 (tool)

RRID:SCR_007255

Portal for Macromolecular X-Ray Crystallography to produce and support an integrated suite of programs that allows researchers to determine macromolecular structures by X-ray crystallography, and other biophysical techniques. Used in the education and training of scientists in experimental structural biology for determination and analysis of protein structure.

View all literature mentions

MolProbity (tool)

RRID:SCR_014226

A structure-validation web application which provides an expert-system consultation about the accuracy of a macromolecular structure model, diagnosing local problems and enabling their correction. MolProbity works best as an active validation tool (used as soon as a model is available and during each rebuild/refine loop) and when used for protein and RNA crystal structures, but it may also work well for DNA, ligands and NMR ensembles. It produces coordinates, graphics, and numerical evaluations that integrate with either manual or automated use in systems such as PHENIX, KiNG, or Coot.

View all literature mentions

Schrodinger (tool)

RRID:SCR_014879

Commercial ogranization which provides molecular and drug discovery software and services to researchers. American software company that develops chemical simulation software for use in pharmaceutical, biotechnology, and materials science research. Provides products ranging from general molecular modeling programs to a full suite of chemical simulation and drug design software, including ligand- and structure-based methods.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

HEK293T (tool)

RRID:CVCL_0063

Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions